7 results on '"Hasenfuss, Gerd"'
Search Results
2. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
- Author
-
Mullens, Wilfried, Dauw, Jeroen, Gustafsson, Finn, Mebazaa, Alexandre, Steffel, Jan, Witte, Klaus K., Delgado, Victoria, Linde, Cecilia, Vernooy, Kevin, Anker, Stefan D., Chioncel, Ovidiu, Milicic, Davor, Hasenfuß, Gerd, Ponikowski, Piotr, von Bardeleben, Ralph Stephan, Koehler, Friedrich, Ruschitzka, Frank, Damman, Kevin, Schwammenthal, Ehud, and Testani, Jeffrey M.
- Subjects
- *
ARTIFICIAL implants , *IMPLANTABLE cardioverter-defibrillators , *HEART failure patients , *HEART failure , *CARDIAC pacing , *CARDIOLOGY , *RHYTHM - Abstract
Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter‐defibrillators and long‐term mechanical support. For others, more evidence is still needed before large‐scale implementation can be strongly advised. Of note, devices and drugs can work synergistically in HF as improved disease control with devices can allow for further optimization of drug therapy. Therefore, some devices might already be considered early in the disease trajectory of HF patients, while others might only be reserved for advanced HF. As such, device therapy should be integrated into HF care programmes. Unfortunately, implementation of devices, including those with the greatest evidence, in clinical care pathways is still suboptimal. This clinical consensus document of the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC) describes the physiological rationale behind device‐provided therapy and also device‐guided management, offers an overview of current implantable device options recommended by the guidelines and proposes a new integrated model of device therapy as a part of HF care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
- Author
-
Wolsk, Emil, Kaye, David M., Komtebedde, Jan, Shah, Sanjiv J., Borlaug, Barry A., Burkhoff, Daniel, Kitzman, Dalane W., Cleland, John G., Hasenfuß, Gerd, Hassager, Christian, Møller, Jacob E., and Gustafsson, Finn
- Subjects
- *
HEART beat , *HEART failure patients , *ANGIOTENSIN-receptor blockers , *AEROBIC capacity , *ACE inhibitors - Abstract
Aims: A hallmark of heart failure with preserved ejection fraction (HFpEF) is impaired exercise capacity of varying severity. The main determinant of exercise capacity is cardiac output (CO), however little information is available about the relation between the constituents of CO – heart rate and stroke volume – and exercise capacity in HFpEF. We sought to determine if a heterogeneity in heart rate and stroke volume response to exercise exists in patients with HFpEF and describe possible clinical phenotypes associated with differences in these responses. Methods and results: Data from two prospective trials of HFpEF (n = 108) and a study of healthy participants (n = 42) with invasive haemodynamic measurements during exercise were utilized. Differences in central haemodynamic responses were analysed with regression models. Chronotropic incompetence was present in 39–56% of patients with HFpEF and 3–56% of healthy participants depending on the definition used, but some (n = 47, 44%) had an increase in heart rate similar to that of healthy controls. Patients with HFpEF had a smaller increase in their stroke volume index (SVI) (HFpEF: +4 ± 10 mL/m2, healthy participants: +24 ± 12 mL/m2, P < 0.0001), indeed, SVI fell in 28% of patients at peak exercise. Higher body mass index and lower SVI at rest were associated with smaller increases in heart rate during exercise, whereas higher resting heart rate, and angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker use were associated with a greater increase in SVI in patients with HFpEF. Conclusion: The haemodynamic response to exercise was very heterogeneous among patients with HFpEF, with chronotropic incompetence observed in up to 56%, and 28% had impaired increase in SVI. This suggests that haemodynamic exercise testing may be useful to identify which HFpEF patients may benefit from interventions targeting stroke volume and chronotropic response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
- Author
-
Emami, Amir, Saitoh, Masakazu, Valentova, Miroslava, Sandek, Anja, Evertz, Ruben, Ebner, Nicole, Loncar, Goran, Springer, Jochen, Doehner, Wolfram, Lainscak, Mitja, Hasenfuß, Gerd, Anker, Stefan D., and von Haehling, Stephan
- Subjects
- *
HEART failure patients , *SARCOPENIA , *CACHEXIA , *EXERCISE , *CLINICAL trials , *BODY composition , *COMPARATIVE studies , *HEART failure , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MUSCLE strength , *QUALITY of life , *RESEARCH , *COMORBIDITY , *EVALUATION research , *SKELETAL muscle , *EXERCISE tolerance , *PHOTON absorptiometry , *DIAGNOSIS - Abstract
Aims: Changes in heart failure (HF) patients' body composition may be associated with reduced exercise capacity. The aim of the present study was to determine the overlap in wasting syndromes in HF (cachexia and sarcopenia) and to compare their functional impact.Methods and Results: We prospectively enrolled 207 ambulatory male patients with clinically stable chronic HF. All patients underwent a standardized protocol examining functional capacity, body composition, and quality of life (QoL). Cachexia was present in 39 (18.8%) of 207 patients, 14 of whom also fulfilled the characteristics of sarcopenia (sarcopenia + cachexia group, 6.7%), whereas 25 did not (cachectic HF group, 12.1%). Sarcopenia without cachexia was present in 30 patients (sarcopenic HF group, 14.4%). A total of 44 patients (21.3%) presented with sarcopenia; however, 138 patients showed no signs of wasting (no wasting group, 66%). Patients with sarcopenia had lower strength and exercise capacity than both the no wasting and the cachectic HF group. Handgrip strength, quadriceps strength, peak oxygen uptake (VO2 ), distance in the 6-minute walk test (6MWT), and QoL results were lowest in the sarcopenia + cachexia group vs. the no wasting group (P < 0.05 for all). Likewise, the sarcopenic HF group showed lower handgrip strength, quadriceps strength, 6MWT, peak VO2 , and QoL results vs. the no wasting group (P < 0.05 for all).Conclusion: Losing muscle with or without weight loss appears to have a more pronounced role than weight loss alone with regard to functional capacity and QoL among male patients with chronic HF.Clinical Trial Registration: ClinicalTrials.gov Identifier NCT01872299. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
5. Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
- Author
-
Petutschnigg, Johannes, Ferreira, João Pedro, Holzendorf, Volker, Trippel, Tobias D., Hashemi, Djawid, Wachter, Rolf, Herrmann‐Lingen, Christoph, Hasenfuß, Gerd, Zannad, Faiez, Pieske, Burkert, Edelmann, Frank, and Herrmann-Lingen, Christoph
- Subjects
- *
BODY composition , *HEART failure patients , *HEART failure , *AEROBIC capacity , *SPIRONOLACTONE , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ALDOSTERONE antagonists , *RESEARCH funding , *STROKE volume (Cardiac output) , *ADIPOSE tissues , *PHENOTYPES - Published
- 2020
- Full Text
- View/download PDF
6. Exercise training in Diastolic Heart Failure (Ex- DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial.
- Author
-
Edelmann, Frank, Bobenko, Anna, Gelbrich, Götz, Hasenfuss, Gerd, Herrmann-Lingen, Christoph, Duvinage, André, Schwarz, Silja, Mende, Meinhard, Prettin, Christiane, Trippel, Tobias, Lindhorst, Ruhdja, Morris, Daniel, Pieske-Kraigher, Elisabeth, Nolte, Kathleen, Düngen, Hans-Dirk, Wachter, Rolf, Halle, Martin, and Pieske, Burkert
- Subjects
- *
EXERCISE physiology , *HEART failure treatment , *HEART failure patients , *RANDOMIZED controlled trials , *DISEASE prevalence - Abstract
Heart failure with preserved ejection fraction ( HFpEF) is a common disease with high incidence and increasing prevalence. Patients suffer from functional limitation, poor health-related quality of life, and reduced prognosis. A pilot study in a smaller group of HFpEF patients showed that structured, supervised exercise training ( ET) improves maximal exercise capacity, diastolic function, and physical quality of life. However, the long-term effects of ET on patient-related outcomes remain unclear in HFpEF. The primary objective of the Exercise training in Diastolic Heart Failure (Ex-DHF) trial is to investigate whether a 12 month supervised ET can improve a clinically meaningful composite outcome score in HFpEF patients. Components of the outcome score are all-cause mortality, hospitalizations, NYHA functional class, global self-rated health, maximal exercise capacity, and diastolic function. After undergoing baseline assessments to determine whether ET can be performed safely, 320 patients at 11 trial sites with stable HFpEF are randomized 1:1 to supervised ET in addition to usual care or to usual care alone. Patients randomized to ET perform supervised endurance/resistance ET (3 times/week at a certified training centre) for 12 months. At baseline and during follow-up, anthropometry, echocardiography, cardiopulmonary exercise testing, and health-related quality of life evaluation are performed. Blood samples are collected to examine various biomarkers. Overall physical activity, training sessions, and adherence are monitored and documented throughout the study using patient diaries, heart rate monitors, and accelerometers. The Ex- DHF trial is the first multicentre trial to assess the long-term effects of a supervised ET programme on different outcome measures in patients with HFpEF. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo- DHF trial.
- Author
-
Edelmann, Frank, Holzendorf, Volker, Wachter, Rolf, Nolte, Kathleen, Schmidt, Albrecht G., Kraigher‐Krainer, Elisabeth, Duvinage, André, Unkelbach, Ines, Düngen, Hans‐Dirk, Tschöpe, Carsten, Herrmann‐Lingen, Christoph, Halle, Martin, Hasenfuss, Gerd, Gelbrich, Götz, Stough, Wendy Gattis, and Pieske, Burkert M.
- Subjects
- *
GALECTINS , *HEART failure patients , *BIOMARKERS , *ALDOSTERONE , *FIBROSIS , *INFLAMMATION , *SPIRONOLACTONE , *BRAIN natriuretic factor - Abstract
Aims Galectin-3 is a marker of myocardial fibrosis and mediates aldosterone-induced cardiovascular inflammation and fibrosis. Characteristics of galectin-3 and its response to spironolactone have not been evaluated in heart failure with preserved ejection fraction ( HFpEF). The aim of this study was to determine the association between galectin-3 levels and patient characteristics in HFpEF; to evaluate the interaction between spironolactone and galectin-3 levels; and to assess the association between galectin-3 and clinical outcomes. Methods and results Aldo- DHF investigated spironolactone 25 mg once daily vs. placebo for 12 months in patients with NYHA class II-III, LVEF ≥50%, grade ≥ I diastolic dysfunction, and peakVO2 ≤ 25 mL/kg/min. Galectin-3 levels were obtained at baseline, and at 6 and 12 months. The association between baseline galectin-3, change in galectin-3, and all-cause death or hospitalization was evaluated, and the interaction between galectin-3 and treatment was assessed. Median baseline galectin-3 was 12.1 ng/ mL. After multivariable adjustment, baseline galectin-3 inversely correlated with peak VO2 ( P = 0.021), 6 min walk distance ( P = 0.002), and Short Form 36 ( SF-36) physical functioning ( P = 0.001), and directly correlated with NYHA class ( P = 0.007). Baseline NT-proBNP correlated with E/e' velocity ratio ( P ≤ 0.001), left atrial volume index ( P < 0.001), and LV mass index ( P = 0.009). Increasing galectin-3 at 6 or 12 months was associated with all-cause death or hospitalization independent of treatment arm [hazard ratio ( HR) 3.319, 95% confidence interval ( CI) 1.214-9.07, P = 0.019] and NT-proBNP ( HR 3.127, 95% CI 1.144-8.549, P = 0.026). Spironolactone did not influence galectin-3 levels. Conclusion Galectin-3 levels are modestly elevated in patients with stable HFpEF and relate to functional performance and quality of life. Increasing galectin-3 was associated with worse outcome, independent of treatment or NT-proBNP. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.